Diabetes

Emily Eddy, PharmD, BCACP, BC-ADM, CDCES, presents on the ever-expanding world of glucagon-like peptide-1s, now heading toward indications for chronic kidney disease and substance use disorder.

A growing body of evidence suggests that the choice of glucose-lowering therapy may play a critical role in colorectal cancer prevention.

Pharmacists spot diabetes risk early, explain heart- and kidney-protecting meds, decode CGM data, and find affordable support.

Suzanne K. Higginbotham, PharmD, BCACP, CTTS, CDCES, further discusses her APhA 2026 presentation titled “Real-Time. Real Change. Rethinking CGM for Today's Patient.”

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, and Staci-Marie Norman, PharmD, CDCES, FAPhA, present on updates to the ADA Standards of Care in Diabetes.

In a bonus episode of the Over the Counter podcast, William A. Bryson, PharmD, joined to help celebrate Diabetes Alert Day—recognized annually on the fourth Tuesday in March.

Lilly’s once-weekly retatrutide lowers A1C up to 2% and drives nearly 17% weight loss in type 2 diabetes, signaling a powerful triple-agonist shift.

The FDA clears the highest-dose weekly semaglutide for obesity, showing 20.7% mean weight loss with the same blood sugar-lowering effects.

With ongoing concerns about the safety and formulation of compounded GLP-1s, Annie Lambert, PharmD, BCSCP, added her expert insights into the recent crackdown of these products.

Combined with nutritional interventions, semaglutide also demonstrates greater weight loss compared with dulaglutide.

Clinical pharmacists boost A1c control and eye and foot screening for Spanish-speaking adults with diabetes, revealing why culturally fluent care matters.

Previously, bimagrumab monotherapy in adults with type 2 diabetes led to a 20.5% reduction in total body fat mass and a 0.76 percentage point decrease in hemoglobin A1c.

In older adults with type 2 diabetes, low body mass index signals higher mortality risk.

Episode 8 explores the real-world evidence, clinical trial data, and overall application of finerenone for pharmacists and their patients.

FDA targets telehealth ads for compounded glucagon-like peptide-1s, warning of misleading claims, hidden sources, and safety risks amid social media hype.

A large study links an early A1c under 6.5% to fewer eye and nerve complications, urging pharmacists to intensify control and monitor retinopathy.

Orforglipron beats oral semaglutide in A1C and weight loss in a head-to-head study for type 2 diabetes.

Navitus Health Solutions conducted a survey of 2000 US adults who have been taking glucagon-like peptide-1 therapies for the past 2 years.

Novo Nordisk’s CagriSema drives 23% weight loss in REDEFINE 4 but misses noninferiority compared with tirzepatide, shaping the next wave of obesity drugs.

New data links glucagon-like peptide-1s to fewer aneurysm ruptures and lower death risk, guiding pharmacists on safer stroke prevention.

Pharmacists help explain the complex evidence, address fears around injections and cost, and help patients integrate lifestyle changes alongside pharmacologic therapy for diabetes care.

Using the PRIME program’s framework, researchers explore a digital-health and pharmacy-based lifestyle intervention for improving risk factors among patients with prediabetes.

Amid common patient threats stemming from severe hypoglycemia, researchers explore how proactive pharmacist outreach can translate to safer prescribing regimens for patients with diabetes.

Amid evolving standards of care in the management of diabetes, researchers explore the role of pharmacists in facilitating continuous glucose monitoring education.

GLP-1 therapies lower C-reactive protein and tumor necrosis factor-alpha, signaling cardiovascular protection; pharmacists tackle cost